NAPRT Silencing in FH-Deficient Renal Cell Carcinoma Confers Therapeutic Vulnerabilities via NAD+ DepletionKatelyn J. Noronha, Ranjit S. Bindra|Molecular Cancer Research|2024Cited by 5